Comment from Abbott

Summary: Abbott Laboratories supports the FDA's intent to exempt certain Class II clinical toxicology test system devices from premarket notification requirements. They argue that existing performance and validation testing for federal drug testing programs already ensures safety and effectiveness, while also recommending clarifications on collection systems and a modernization of product codes.